FIGURE 1.

Schematic presentation of study interventions and immunosuppressive regimen. Patients received induction therapy with alemtuzumab (Campath^®) 15 mg on day 0 and day 1 after transplantation [Tx]). Prednisolone started on day 0 with 500 mg, 250 mg on day 1, 125 mg on day 2, 100 mg on day 3, 50 mg on day 4, and 10 mg/day from day 5, then reduced to 7.5 mg after 3 months (week 12) and to 5 mg at 6 months (week 26). Target trough level of everolimus (Certican^®) was 3‐8 ng/mL. The tacrolimus (Advagraf^®) target was 8‐10 ng/mL the first 6 weeks post Tx, 4‐7 ng/mL from 6 to 24 weeks, and lowered to 1.5‐3 ng/mL at week 26. A renal biopsy was performed 24 weeks after transplantation, before MSC infusion, and 52 weeks after transplantation. In week 25 and week 26 1‐2 × 10⁶/kg allogeneic MSC were infused. W, weeks; Tx, transplantation; MSC, mesenchymal stromal cells; C0, trough level